Loading patent…
AssigneeGW Research Limited
InventorsGeoffrey GUY, Stephen WRIGHT, James BRODIE, Marie WOOLLEY-ROBERTS, Rafael MALDONADO, Daniela PAROLARO, Livio LUONGO, Joanna NEILL
Estimating the term…
The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.
A method of treating one or more symptoms or disease characteristics associated with autistic spectrum disorder (ASD) or ASD-associated disorders, as defined by DSM-IV, in a subject in need thereof, the method comprising administering cannabidivarin to the subject, wherein the one or more symptoms or disease characteristics are one or more of:
A method of treating one or more symptoms or disease characteristics associated with autistic spectrum disorder (ASD) or ASD-associated disorders, as defined by DSM-V, in a subject in need thereof, the method comprising administering cannabidivarin to the subject, wherein the one or more symptoms or disease characteristics are one or more of:
-32. (canceled)
A method of treating schizophrenia in a subject in need thereof, comprising administering an effective amount of cannabidivarin (CBDV) to the subject.
A method of treating cognitive dysfunction in a subject in need thereof, comprising administering an effective amount of cannabidivarin (CBDV) to the subject.
Dependencies are inferred from the claim text.